|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions

News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia


Market Summary
News
IPOs

Company Profiles

Companies
Events

Research Store

Biotech Events
Post an Event

Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
ASINEX Ltd. And SIENABIOTECH Announce Lead Generation Collaboration
10/19/2005 5:10:38 PM
ASINEX Ltd, a worldwide leader in lead generation and lead optimization, will perform computational work for SIENABIOTECH S.p.A., an integrated drug discovery company.
ASINEX's computational department based on the information provided by SIENABIOTECH (undisclosed target & undisclosed set of small molecules active toward such target) will create different pharmacophore models and use the results to rank the whole in-house ASINEX library (Platinum Collection 120,000 compounds) based on the resulting docking score.
Georg C. Terstappen, V.P. Discovery Research of SIENABIOTECH said "Through this collaboration we expect to enhance the efficiency of our integrated drug discovery process which employs state-of-the-art platform technologies. Using ASINEX' compound collection, flexible docking and de novo ligand design technologies, we believe we can increase the chances of identifying high-quality leads."
"ASINEX's computational team, with their efficient lead generation and drug design solutions, have proven to be a creative partner for biotech companies. Our computational department is a part of ASINEX's 'chemistry driven' integrated drug discovery service. Today we are delighted to announce ASINEX's deal with Sienabiotech and we are looking forward to establish a long-term relationship which will also include chemistry services", said Dmitri Genis, ASINEX CEO
|
|
|
|
|
|
|
|
|
|
|